Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4772MR)

This product GTTS-WQ4772MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4772MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11451MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ7512MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ1105MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ12635MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ5293MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ10167MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ6651MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ7107MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FE 999301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW